Suicidality, Violence, and Mania Caused by Selective Serotonin Reuptake Inhibitors: A Review and Analysis

Ethical Human Sciences and Services

Volumn 5, Issue 3, 2003, Pages 225-246

  Breggin, Peter R ^a  

^a Department of Psychiatry ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; COCAINE; CORTISONE; DOSULEPIN; DOXEPIN; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; ISOTRETINOIN; LYSERGIDE; METHAMPHETAMINE; MIANSERIN; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PSYCHOSTIMULANT AGENT; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TESTOSTERONE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGITATED DEPRESSION; AGITATION; AKATHISIA; AMNESIA; ANXIETY; APATHY; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CRIMINAL JUSTICE; DELIRIUM; DEPERSONALIZATION; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC ERROR; DISEASE EXACERBATION; DRUG INDUCED DISEASE; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; DRUGGED FEELING; EUPHORIA; EVIDENCE BASED MEDICINE; FORENSIC MEDICINE; HALLUCINATION; HEART PALPITATION; HOSTILITY; HUMAN; HYPERHIDROSIS; INSOMNIA; LEGAL LIABILITY; LIBIDO DISORDER; MALPRACTICE; MANIA; MANIC PSYCHOSIS; MENTAL INSTABILITY; NERVOUSNESS; NEUROSIS; OBSESSION; PARANOIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SIDE EFFECT; SUICIDAL BEHAVIOR; TREMOR; VIOLENCE;

EID: 1842480977     PISSN: 1523150X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. American Psychiatric Association. (1993). Practice guidelines for major depressive disorder in adults. Washington, DC: Author.
2. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
3. American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed.-rev.). Washington, DC: Author.
4. Bastani, J., Troester, M., & Bastani, A. (1996). Serotonin syndrome and fluvoxamine: A case study. Nebraska Medical Journal, 81, 107-109.
5. Beasley, C. (1988, November 8). Activation and sedation in fluoxetine clinical studies. Unpublished in-house document generated by Eli Lilly and Company during the FDA-approval process of Prozac for depression and obtained during discovery for Fentress v. Shay Communications et al. Fentress Trial Exhibit 70.
6. Borg, S., & Brodin, K. (1996). Antidepressant drugs. In M. N. G. Dukes (Ed.), Meyler's side effects of drugs (13th ed., pp. 31-80). New York: Elsevier.
7. Bost, R., & Kemp, P. (1992). A possible association between fluoxetine use and suicide. Journal of Analytic Toxicology, 16, 142-145.
8. Breggin, P. (1992). A case of fluoxetine-induced stimulant side effects with suicidal ideation associated with a possible withdrawal reaction ("crashing"). International Journal of Risk & Safety in Medicine, 3, 325-328.
9. Breggin, P. (1994, October 17-19). Joyce Fentress et al. v. Shea Communications et al. [The Wesbecker Case]. Jefferson Circuit Court, Division, 1, Louisville, Kentucky, No. 90-CI-06033, Volume XVI.
10. Breggin, P. (1997). Brain-disabling treatments in psychiatry: Drugs, electroshock, and the role of the FDA. New York: Springer.
11. Breggin, P. (1998). Analysis of adverse behavioral effects of benzodiazepines with a discussion of drawing scientific conclusions from the FDA's Spontaneous Reporting System. Journal of Mind and Behavior, 19, 21-50.
12. Breggin, P. (2001). The antidepressant fact book. Cambridge, MA: Perseus Books.
13. Breggin, P. (2002). Fluvoxamine as a cause of stimulation, mania, and aggression with a critical analysis of the FDA-approved label. International Journal of Risk and Safety in Medicine, 14, 71-86.
14. Breggin, P., & Breggin, G. (1994). Talking back to Prozac: What doctors aren't telling you about today's most controversial drug. New York: St. Martin's Press.
15. Breggin, P., & Cohen, D. (1999). Your drug may be your problem: How and why to stop taking psychiatric medications. Cambridge, MA: Perseus Books.
16. British Medical Association and Royal Pharmaceutical Society of Great Britain. (1991, September). British National Formulary (BNF). London, England: the Pharmaceutical Press.
17. Burrai, C., Bocchetta, A., & Zompo, M. (1991). Mania and fluvoxamine. American Journal of Psychiatry, 148, 1263-1264.
18. Christensen, R. (1995). Paroxetine-induced mania. American Journal of Psychiatry, 152, 1439-1400.
19. Constantino, J., Liberman, M., & Kincaid, M. (1997). Effects of serotonin reuptake inhibitors on aggressive behavior in psychiatric hospitalized adolescents: Results of an open trial. Journal of Child and Adolescent Psychopharmacology, 7, 31-44.
20. Creaney, W., Murray, I., & Healy, D. (1991). Antidepressant-induced suicidal ideation. Human Psychopharmacology, 6, 329-332.
21. Dasgupta, K. (1990). Additional cases of suicidal ideation associated with fluoxetine. American Journal of Psychiatry, 147, 1570.
22. Donovan, S., Clayton, A., Beeharry M., Jones, S., Kirk, C., Waters, K., et al. (2000). Deliberate self-harm and antidepressant drugs: Investigation of a possible link. British Journal of Psychiatry, 177, 551-556.
23. Donovan, S., Kelleher, M., Lambourn, J., & Foster, T. (1999). The occurrence of suicide following the prescription of antidepressant drugs. Archives of Suicide Research, 5, 181-192.
24. Dorevitch, A., Frankel, Y., Bar-Halperin, A., Aronzon, R., & Zilberman, L. (1993). Fluvoxamine-associated manic behavior: A case series. Annals of Pharmacotherapy, 27, 1455-1457.
25. Drug Facts and Comparisons. (2003). St. Louis: Facts and Comparisons.
26. Ebert, D., Albert, R., May, A., Merz, A., Murata, H., Stosiek, I., et al. (1997). The serotonin syndrome and psychosis-like side effects of fluvoxamine in clinical use - An estimation of incidence. European Neuro-Pharmacology, 7, 71-74.
27. Editorials: 5-HT blockers and all that. (1990). The Lancet, 336, 345-346.
28. Emslie, G. J., Rush, A. J., Weinberg, W. A., Kowatch, R. A., Hughes, C. W., Carmody, T., et al. (1997). A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry, 54, 1031-1037.
29. Fentress et al. v. Shea Communications et al. (1994) [The Wesbecker Case]. Jefferson Circuit Court, Division 1, Louisville, Kentucky, No. 90-CI-06033, Volume XVI.
30. Fisher, S., Bryant, S., & Kent, T. (1993). Postmarketing surveillance by patient self-monitoring: Trazodone versus fluoxetine. Journal of Clinical Psychopharmacology, 13, 235-242.
31. Fisher, S., Kent T., & Bryant, S. (1995). Postmarketing surveillance by patient self-monitoring: Preliminary data for sertraline versus fluoxetine. Journal of Clinical Psychiatry, 56, 288-296.
32. Food and Drug Administration. (1991, September 20). Transcript of Psychopharmacologic Drugs Advisory Committee: 34th meeting. Rockville, MD: Department of Health and Human Services, Public Health Service, Food and Drug Administration.
33. Food and Drug Administration. (2003a, June 19). FDA statement regarding the anti-depressant Paxil for pediatric population. Rockville, MD: Department of Health and Human Services.
34. Food and Drug Administration (2003b, October 27). FDA public health advisory: Reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD). Rockville, MD: Department of Health and Human Services.
35. Frankenfield, D., Baker, S., Lange, W., Caplan, Y., & Smialek, J. (1994). Fluoxetine and violent death in Maryland. Forensic Science International, 64, 107-117.
36. Glenmullen, J. (2000). Prozac backlash. New York: Simon & Schuster.
37. Gorman, J., Liebowitz, M., Fyer, A., Goetz, D., Campeas, R., Fyer, M., et al. (1987). An open trial of fluoxetine in the treatment of panic disorder. Journal of Clinical Psychopharmacology, 7, 329-332.
38. Grimsley, S., & Jann, M. (1992). Paroxetine, sertraline, and fluvoxamine: New selective serotonin reuptake inhibitors. Clinical Pharmacy, 11, 930-957.
39. Gualtieri, C. (1991). Paradoxical effects of fluoxetine. Journal of Clinical Psychopharmacology, 11, 393-394.
40. Healy, D. (1994). The fluoxetine and suicide controversy: A review of the evidence. CNS Drugs, 1, 223-231.
41. Healy, D. (2000). Emergency of antidepressant-induced suicidality. Primary Care Psychiatry, 2000, 6, 23-28.
42. Healy, D. (2003). Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychotherapy and Psychosomatics, 72, 71-79.
43. Hoehn-Saric, R., Lipsey, J., & McLeod, D. (1990). Apathy and indifference in patients on fluvoxamine and fluoxetine. Journal of Clinical Psychopharmacology, 10, 343-345.
44. Hoover, C. (1990). Additional cases of suicidal ideation associated with fluoxetine. American Journal of Psychiatry, 147, 1569-1570.
45. Howland, R. (1996). Induction of mania with serotonin reuptake inhibitors. Journal of Clinical Psychopharmacology, 16, 425-427.
46. Jain, J., Birmaher, B., Garcia, M., Al-Shabbout, M., & Ryan, N. (1992). Fluoxetine in children and adolescents with mood disorders: A chart review of efficacy and adverse reactions. Journal of Child and Adolescent Psychopharmacology, 2, 259-265.
47. Jick, S., Dean, A., & Jick, H. (1995). Antidepressants and suicide. British Medical Journal, 310, 215-218.
48. Kapit, R. (1986a, March). Safety review of NDA 18-936 [Prozac]. Internal document of the Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research.
49. Kapit, R. (1986b, December 17). Response to Dr. Laughren's Q's regarding review of safety update, memo #3. (NDA 18-936). Internal document of the Department of Health and Human Services, Public Health Service, Food and Drug Administration, Center for Drug Evaluation and Research, Rockville, MD.
50. Khan, A., Khan, S., Leventhal, R., & Brown, W. (2001). Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: A replication analysis of the Food and Drug Administration database. International Journal of Neuropsychopharmacology, 4, 113-118.
51. Khan, A., Warner, H., & Brown, W. (2000). Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: An analysis of the Food and Drug Administration database. Archives of General Psychiatry, 57, 311-317.
52. King, R., Riddle, M., Chappell, P., Hardin, M., Anderson, G., Lombroso, P., et al. (1991, March). Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 179-186.
53. Koizumi, J. (1991). Fluoxetine and suicidal ideation. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 695.
54. Lane, R. (1998). SSRI-induced extrapyramidal side-effects and akathisia: Implications for treatment. Journal of Psychopharmacology, 12, 192-214.
55. Leonard, B. (1992). Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs, 43(Suppl. 2), 3-10.
56. Levine, L., Rosenblatt, S., & Bosomworth, J. (1987). Use of a serotonin reuptake inhibitor, fluoxetine, in the treatment of obesity. International Journal of Obesity, 11(Suppl. 3), 185-190.
57. Lipinski, Jr., J., Mallaya, G., Zimmerman, P., & Pope, Jr., H. (1989). Fluoxetine-induced akathisia: Clinical and theoretical implications. Journal of Clinical Psychiatry, 50, 339-352.
58. Marangell, L., Yudofsky, S., & Silver, J. (1999). Psychopharmacology and electroconvulsive therapy. In R. Hales, S. Yudofsky, & J. Talbott (Eds.), The American Psychiatric Press textbook of psychiatry (pp. 1025-1132). Washington, DC: American Psychiatric Press.
59. Masand, P., Gupta, S., & Dewan, M. (1991). Suicidal ideation related to fluoxetine treatment. New England Journal of Medicine, 324, 420.
60. Muijen, M., Roy, D., Silverstone, T., Mehmet, A., & Christie, M. (1988). A comparative clinical trial of fluoxetine, mianserin and placebo in depressed outpatients. Acta Psychiatrica Scandinavica, 78, 384-390.
61. Okada, F., & Okajima, K. (2001). Violent acts associated with fluvoxamine treatment. Journal of Psychiatry & Neuroscience, 26, 339-340.
62. Oldroyd, J. (1997). Paroxetine-induced mania. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 721-722.
63. Peyre, R., Verdous, H., & Bourgeois, M. (1992, January). Fluvoxamine: Study of treatment effect on a group of 189 hospitalized patients with depression. Encéphale, 18(1), 73-74.
64. Physicians' Desk Reference. (2001). Montvale, NJ: Medical Economics.
65. Physicians' Desk Reference. (2003). Montvale, NJ: Medical Economics.
66. Preda, A., MacLean, R., Mazure, C., & Bowers, M. (2001). Antidepressant-associated mania and psychosis resulting in psychiatric admission. Journal of Clinical Psychiatry, 62, 30-33.
67. Public Citizen Health Research Group. (1991, May 23). Re: Citizens petition for revision of fluoxetine (Prozac) labeling [Letter to David Kessler, Commissioner of the Food and Drug Administration]. Washington, DC: Public Citizen.
68. Riddle, M., King, R., Hardin, M., Scahill, L., Ort, S., Chappell, P., et al. (1990/1991). Behavioral side effects of fluoxetine in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 1, 193-198.
69. Rothschild, A., & Locke, C. (1991). Re-exposure to fluoxetine after serious suicide attempts by three patients: The role of akathisia. Journal of Clinical Psychiatry, 52, 491-493.
70. Sim, F. (2000). A single dose of fluvoxamine associated with an acute psychotic reaction. Canadian Journal of Psychiatry, 45, 762.
71. Teicher, M., Glod, C., & Cole, J. (1990). Emergence of intense suicidal preoccupations during fluoxetine treatment. American Journal of Psychiatry, 147, 207-210.
72. Teicher, M., Glod, C., & Cole, J. (1993). Antidepressant drugs and the emergence of suicidal tendencies. Drug Safety, 8, 182-212.
73. Troisi, A., Vicario, E., Nuccetelli, F., Ciani, N., & Pasini A. (1995). Effects of fluoxetine on aggressive behavior in adult inpatients with mental retardation and epilepsy. Pharmacopsychiatry, 28, 73-76.
74. Van Putten, T. (1974). Why do schizophrenic patients refuse to take their drugs? Archives of General Psychiatry, 31, 67-72.
75. Van Putten, T. (1975). The many faces of akathisia. Comprehensive Psychiatry, 16, 43-47.
76. Wilkinson, D. (1999). Loss of anxiety and increased aggression in a 15-year-old boy taking fluoxetine. Journal of Psychopharmacology, 13, 420.
77. Wirshing, W., Van Putten, T., Rosenberg, J., Marder, S., Ames, D., & Hicks-Gray, T. (1992). Fluoxetine, akathisia, and suicidality: Is there a connection? Archives of General Psychiatry, 49, 580-581.